Physician profile
Asif Masood
NPI 1760448013
$14,000.85
in general payments reported to CMS, 2019-2025
65 companies · $2,314 in 2025
The $2,314 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,624 · 2020: $2,247 · 2021: $791 · 2022: $2,005 · 2023: $2,223 · 2024: $1,798 · 2025: $2,314.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,143 · Education: $192.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,142.56 |
| Education | $192.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,934.56 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $928.80 | 2019-2025 | Enhertu, Imfinzi, Lynparza |
| Pfizer INC. | $762.46 | 2019-2025 | |
| Genzyme Corporation | $553.81 | 2019-2025 | |
| Lilly USA, LLC | $540.04 | 2019-2025 | Jaypirca, Verzenio, Retevmo |
| Eisai INC. | $514.18 | 2019-2025 | |
| Janssen Biotech, INC. | $476.65 | 2019-2025 | Erleada, Rybrevant, Balversa |
| Bayer Healthcare Pharmaceuticals INC. | $437.75 | 2019-2025 | |
| Incyte Corporation | $435.40 | 2019-2025 | Zynyz, Jakafi, Monjuvi |
| Abbvie INC. | $397.33 | 2019-2025 | |
| Seagen INC. | $352.27 | 2019-2023 | Tukysa, Adcetris |
| Amgen INC. | $343.43 | 2019-2023 | Kyprolis, Vectibix, Xgeva |
| Boehringer Ingelheim Pharmaceuticals, INC. | $336.03 | 2019-2025 | Gilotrif |
| Glaxosmithkline, LLC. | $326.86 | 2021-2025 | Ojjaara, Jemperli, Zejula |
| Exelixis INC. | $321.76 | 2019-2025 | Cabometyx |
Show all 65 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $273.13 | 2019-2022 | |
| Celgene Corporation | $272.63 | 2019-2025 | Reblozyl |
| Ipsen Biopharmaceuticals, INC | $228.76 | 2020-2025 | Onivyde, Somatuline Depot, Tazverik |
| Emd Serono, INC. | $219.29 | 2019-2025 | Bavencio |
| E.R. Squibb & Sons, L.L.C. | $214.08 | 2019-2023 | Opdivo |
| Takeda Pharmaceuticals U.S.A., INC. | $210.32 | 2019-2025 | Ninlaro, Fruzaqla, Iclusig |
| Rigel Pharmaceuticals, INC. | $209.34 | 2020-2024 | Rezlidhia, Tavalisse |
| Gilead Sciences, INC. | $201.72 | 2021-2025 | Trodelvy |
| Tesaro, INC. | $201.68 | 2019 | |
| Daiichi Sankyo INC. | $199.14 | 2019-2025 | Enhertu |
| Genentech USA, INC. | $199.12 | 2019-2025 | Tecentriq, Phesgo, Lunsumio |
| Adc Therapeutics America, INC. | $182.57 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $174.57 | 2022-2025 | Libtayo |
| Mirati Therapeutics, INC. | $159.86 | 2023-2024 | Krazati |
| Puma Biotechnology, INC. | $159.80 | 2022-2025 | Nerlynx |
| Pharmacyclics LLC, An Abbvie Company | $159.35 | 2019-2023 | Imbruvica |
| Alexion Pharmaceuticals, INC. | $148.29 | 2019-2023 | Ultomiris |
| Array Biopharma INC | $148.19 | 2020-2025 | Mektovi, Braftovi, Lorbrena |
| Caris Mpi, INC. | $140.41 | 2025 | Mi Cancer Seek |
| Beigene USA, INC. | $130.22 | 2021-2024 | Brukinsa |
| Dova Pharmaceuticals | $108.22 | 2019-2021 | |
| Adaptive Biotechnologies Corporation | $103.51 | 2022-2024 | Clonoseq |
| Sobi, INC | $102.89 | 2022-2025 | |
| Aveo Pharmaceuticals, INC. | $102.45 | 2021-2025 | Fotivda |
| Karyopharm Therapeutics INC. | $95.51 | 2020-2023 | Xpovio |
| Blueprint Medicines Corporation | $93.07 | 2024 | Ayvakit |
| Pharmaessentia USA Corporation | $89.35 | 2023-2025 | Besremi |
| Astellas Pharma US INC | $81.25 | 2019-2023 | Padcev, Xospata |
| Alnylam Pharmaceuticals INC. | $69.41 | 2023-2024 | Givlaari |
| Clovis Oncology, INC. | $63.01 | 2019-2020 | |
| Kite Pharma, INC. | $50.96 | 2022-2023 | |
| Global Blood Therapeutics, INC. | $50.37 | 2021-2022 | |
| Azurity Pharmaceuticals, INC. | $47.62 | 2025 | Danziten, Vivimusta |
| Epizyme, INC. | $47.35 | 2020-2022 | |
| G1 Therapeutics, INC. | $43.24 | 2022-2023 | Cosela |
| Geron Corporation | $41.20 | 2025 | Rytelo |
| Recordati_rare_diseases_inc. | $39.73 | 2024-2025 | Sylvant |
| Lexicon Pharmaceuticals, INC. | $30.65 | 2019-2020 | |
| Apellis Pharmaceuticals, INC. | $30.29 | 2023 | Empaveli |
| Beone Medicines USA, INC. | $29.74 | 2025 | Brukinsa |
| Pharmacosmos Therapeutics INC. | $27.74 | 2024 | Cosela |
| Teva Pharmaceuticals USA, INC. | $26.87 | 2019 | |
| Verity Pharmaceuticals INC. | $22.47 | 2023 | Trelstar |
| Dendreon Pharmaceuticals LLC | $17.87 | 2025 | Provenge |
| Tersera Therapeutics LLC | $17.18 | 2021 | |
| Sun Pharmaceutical Industries INC. | $16.38 | 2023 | Yonsa, Odomzo |
| Deciphera Pharmaceuticals INC. | $16.04 | 2021 | |
| Stemline Therapeutics INC. | $15.01 | 2024 | Orserdu |
| Taiho Oncology, INC. | $14.80 | 2022 | |
| Coherus Oncology, INC. | $12.87 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Asif Masood listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.